HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nestle

This article was originally published in The Tan Sheet

Executive Summary

Probiotic supplement LC1 discontinued due to lower-than-expected sales, firm says. Nestle stopped selling the supplement in November, although the probiotic is still available as a chilled dairy product or yogurt in some countries. Company speculates powder form of LC1 might have kept sales down but says it has no plans for U.S. reintroduction in a different form. The Lactobacillus johnsonii-containing powder launched in March at GNC stores and drugstore.com (1"The Tan Sheet" March 6, 2000, p. 4)

You may also be interested in...



Brands Strain To Stand Out In Probiotic Competition

Major brands are stocking retail shelves with dietary supplements containing probiotic bacteria, but the firms face a growing challenge for making their bacterial strains stand out from the competition

Nestle LC1 Probiotic Supplement Launching With Direct Mail, Print Support

Nestle USA is introducing its first dietary supplement product, Nestle LC1, with print ads and direct mail support expected to break the week of March 5.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel